1. Home
  2. WWR vs MAIA Comparison

WWR vs MAIA Comparison

Compare WWR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WWR

Westwater Resources Inc.

BUY

Current Price

$0.41

Market Cap

68.8M

ML Signal

BUY

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.11

Market Cap

69.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WWR
MAIA
Founded
1977
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
69.2M
IPO Year
2006
2022

Fundamental Metrics

Financial Performance
Metric
WWR
MAIA
Price
$0.41
$1.11
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$2.17
★ $12.00
AVG Volume (30 Days)
★ 693.8K
564.0K
Earning Date
11-11-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.33
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$0.87
52 Week High
$1.74
$3.19

Technical Indicators

Market Signals
Indicator
WWR
MAIA
Relative Strength Index (RSI) 24.86 32.19
Support Level $0.38 N/A
Resistance Level $0.45 $1.47
Average True Range (ATR) 0.03 0.05
MACD -0.01 -0.01
Stochastic Oscillator 1.47 11.11

Price Performance

Historical Comparison
WWR
MAIA

About WWR Westwater Resources Inc.

Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: